Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori (Q37201668)

From Wikidata

Jump to navigation Jump to search

scientific article published on 23 February 2009

Language	Label	Description	Also known as
English	Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori	scientific article published on 23 February 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Helicobacter pylori

0 references

Helicobacter pylori infectious disease

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Jyh-Chin Yang

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Yu-Fan Yang

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Yow-Shieng Uang

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Chun-Jung Lin

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Teh-Hong Wang

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

23 February 2009

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

British Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

67

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

503-510

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

6 September 2017

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

6 September 2017

The gastric H,K ATPase as a drug target: past, present, and future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

6 September 2017

The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

6 September 2017

CYP2C19 polymorphism and proton pump inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

6 September 2017

Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

6 September 2017

A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

6 September 2017

Review article: the pharmacology of rabeprazole

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

6 September 2017

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

6 September 2017

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

6 September 2017

Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

26 June 2018

Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

26 June 2018

Simplified calculation of body-surface area.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

26 June 2018

Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

26 June 2018

Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

3 September 2018

Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

3 September 2018

Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

3 September 2018

Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

3 September 2018

Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

3 September 2018

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

3 September 2018

Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

3 September 2018

A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

3 September 2018

What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

3 September 2018

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

3 September 2018

4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

3 September 2018

Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686066

3 September 2018

Helicobacter pylori

1 reference

https://pubmed.ncbi.nlm.nih.gov/19552744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of a new H(+)-K+ ATPase inhibitor (E3810) and its four metabolites in human plasma by high-performance liquid chromatography

1 reference

https://pubmed.ncbi.nlm.nih.gov/19552744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status

1 reference

https://pubmed.ncbi.nlm.nih.gov/19552744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/19552744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/19552744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology

1 reference

https://pubmed.ncbi.nlm.nih.gov/19552744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/19552744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/19552744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism

1 reference

https://pubmed.ncbi.nlm.nih.gov/19552744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication

1 reference

https://pubmed.ncbi.nlm.nih.gov/19552744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2125.2009.03393.X

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37201668&oldid=2143973883"